Sodium-glucose cotransporter-2 (SGLT2) inhibitors, i.e., dapagliflozin [56] and empagliflozin [57], sacubitril-valsartan [58], and a non-steroidal mineralocorticoid receptor antagonist, finerenone [59], have exhibited excellent reno-protective effects against CKD in individuals with diabetes and have received attention as attractive treatment options for CKD. The gene discussed is SLC5A2; the disease is diabetes mellitus.